Multiple Myeloma

Sagar Lonial, MD, FACP, discusses the approval of belantamab mafodotin-blmf and how it addressed an unmet need in relapsed/refractory multiple myeloma.

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.

The FDA has granted a priority review designation to a biologics license application for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma who have received at least 3 previous therapies.

Susan Bal, MD, discusses key trials in the multiple myeloma space.

Thomas G. Martin, MD, discusses the importance of targeted therapy in multiple myeloma, in addition to ongoing research.

Jeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate the need for autologous stem cell transplant in this population.

Joshua Richter, MD, discusses the importance of optimizing these novel therapies to make way for precision medicine in multiple myeloma.

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.

Although the addition of ixazomib to lenalidomide and dexamethasone showed an improvement in progression-free survival in patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant, it was not determined to be of statistical significance.

Luciano J. Costa, MD, PhD, discusses emerging data regarding the use of BCMA-directed bispecific antibodies and antibody-drug conjugates in multiple myeloma.

The first-in-class radioiodinated phospholipid drug conjugate CLR 131 elicited a clinically meaningful overall response rate of 40% in patients with triple-class refractory multiple myeloma who received a total administered dose of 60 mCi or greater.

Marc J. Braunstein, MD, PhD, highlights pivotal research on the use of triplet and quadruplet regimens in the up-front and relapsed/refractory multiple myeloma treatment settings presented during the 2020 ASCO Virtual Scientific Program.

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in ​relapsed/refractory multiple myeloma. 

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Katja Weisel, MD, explains the rationale for the GMMG-CONCEPT trial, details the key interim findings, and provides foresight on future milestones in the field of multiple myeloma.

Shambavi Richard, MD, highlights the rapidly evolving armamentarium ​in multiple myeloma.

The overall response rates with subcutaneous daratumumab proved to be similar to that of the intravenous formulation of the drug irrespective of body weight.

Shambavi Richard, MD, discusses pivotal data in the multiple myeloma paradigm, as well as remaining questions that future research efforts should aim to address.

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

The FDA has granted a priority review to a new drug application for melphalan flufenamide for use in combination with dexamethasone in adult patients with multiple myeloma whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody.

Ajai Chari, MD, discusses the recent approval of belantamab mafodotin in relapsed/refractory multiple myeloma and other emerging agents under exploration in the space.

The European Commission has approved belantamab mafodotin-blmf for the treatment of adult patients with multiple myeloma who have received at least 4 previous therapies, whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody, and who have progressed on their last therapy.